CA2483912A1 - Alcam and alcam modulators - Google Patents

Alcam and alcam modulators Download PDF

Info

Publication number
CA2483912A1
CA2483912A1 CA002483912A CA2483912A CA2483912A1 CA 2483912 A1 CA2483912 A1 CA 2483912A1 CA 002483912 A CA002483912 A CA 002483912A CA 2483912 A CA2483912 A CA 2483912A CA 2483912 A1 CA2483912 A1 CA 2483912A1
Authority
CA
Canada
Prior art keywords
alcam
antibody
cells
ability
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002483912A
Other languages
English (en)
French (fr)
Inventor
Jennie P. Mather
Rong-Hao Li
Mary C. Tsao
Deryk T. Loo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raven Biotechnologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2483912A1 publication Critical patent/CA2483912A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002483912A 2002-05-03 2003-05-02 Alcam and alcam modulators Abandoned CA2483912A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37747902P 2002-05-03 2002-05-03
US60/377,479 2002-05-03
PCT/US2003/014025 WO2003093443A2 (en) 2002-05-03 2003-05-02 Alcam and alcam modulators

Publications (1)

Publication Number Publication Date
CA2483912A1 true CA2483912A1 (en) 2003-11-13

Family

ID=29401505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002483912A Abandoned CA2483912A1 (en) 2002-05-03 2003-05-02 Alcam and alcam modulators

Country Status (7)

Country Link
US (1) US20040048319A1 (https=)
EP (1) EP1501544A4 (https=)
JP (1) JP2005524399A (https=)
CN (1) CN1662254A (https=)
AU (1) AU2003225294A1 (https=)
CA (1) CA2483912A1 (https=)
WO (1) WO2003093443A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565907A1 (en) * 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
AU2006210589B2 (en) 2005-02-02 2011-12-08 Macrogenics West, Inc. ADAM-9 modulators
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
GB0705775D0 (en) * 2007-03-26 2007-05-02 Affitech As Product
WO2008133945A1 (en) * 2007-04-25 2008-11-06 The Trustees Of The University Of Pennsylvania Low level fluorescence detection at the light microscopic level
EP2065399A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy
US20110151580A1 (en) * 2007-11-06 2011-06-23 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient
WO2009068423A2 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
SG168430A1 (en) * 2009-07-22 2011-02-28 Agency Science Tech & Res Molecular signature of human lung cancer initiating cells
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
EP2601216B1 (en) 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
KR101213445B1 (ko) 2011-01-13 2012-12-18 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 암세포의 전이 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물
CA2836873C (en) 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
US10585102B2 (en) * 2012-10-11 2020-03-10 Vanderbilt University Characterization of cancer using detection of activated leukocyte cell adhesion molecule (ALCAM) shedding
US10451628B2 (en) 2014-05-07 2019-10-22 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
CN107849133B (zh) 2015-05-04 2022-08-23 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
EP3325006A4 (en) * 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York METHOD FOR TREATING CD166-EXPRESSIVE CANCER
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
MX2020000435A (es) 2017-07-14 2020-08-17 Cytomx Therapeutics Inc Anticuerpos anti-cd166 y usos de estos.
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
US12415863B2 (en) 2018-10-05 2025-09-16 The Regents Of The University Of Michigan Compositions and methods for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5846535A (en) * 1990-10-12 1998-12-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5968768A (en) * 1993-11-02 1999-10-19 Duke University CD6 ligand encoding sequence
CA2175247A1 (en) * 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
CA2282410A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
FR2796073B1 (fr) * 1999-07-07 2003-08-29 Centre Nat Rech Scient Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Also Published As

Publication number Publication date
WO2003093443A2 (en) 2003-11-13
JP2005524399A (ja) 2005-08-18
CN1662254A (zh) 2005-08-31
EP1501544A4 (en) 2006-06-21
WO2003093443A3 (en) 2004-11-18
US20040048319A1 (en) 2004-03-11
EP1501544A2 (en) 2005-02-02
AU2003225294A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
US8361475B2 (en) ADAM-9 modulators
US20040048319A1 (en) ALCAM and ALCAM modulators
US8440197B2 (en) KID3 and KID3 antibodies that bind thereto
US20110045006A1 (en) LUCA2 and Antibodies That Bind Thereto
EP2094307A2 (en) Tes7 and antibodies that bind thereto
US20060171952A1 (en) JAM-3 and antibodies that bind thereto
MX2007009403A (es) Anticuerpos que se unen a epha2 y metodos para usar los mismos.
HK1107359B (en) Adam-9 modulators
HK1086284B (en) Kid3 and anti-kid3 antibodies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued